Description

BSE notifies opening of the tender offer buyback window for Windlas Biotech Limited, allowing eligible shareholders to tender up to 4,70,000 equity shares at INR 1,000 per share from April 30 to May 7, 2026.

Summary

BSE has announced the opening of the Offer to Buy (Buyback) Acquisition Window for Windlas Biotech Limited. The company proposes to buy back up to 4,70,000 fully paid-up equity shares at INR 1,000 per share via the Tender Offer route, for a maximum aggregate amount of INR 47 crore (excluding transaction costs). The buyback window is open from April 30, 2026 to May 7, 2026 (excluding the SEBI holiday on May 1, 2026).

Key Points

  • Buyback of up to 4,70,000 equity shares (face value INR 5 each), representing 2.23% of total paid-up equity share capital
  • Buyback price: INR 1,000 per equity share, payable in cash
  • Maximum aggregate buyback amount: INR 47,00,00,000 (INR 47 crore), excluding transaction costs
  • Mechanism: Tender Offer route via Stock Exchange acquisition window
  • Record date for eligible shareholders: Friday, April 24, 2026
  • Offer window: April 30, 2026 to May 7, 2026 (SEBI holiday May 1, 2026 excluded)
  • Governed by SEBI circular CFD/DCR2/CIR/P/2016/131 dated December 9, 2016 and BSE notice no. 20170210-16, 20190424-35

Regulatory Changes

No new regulatory changes introduced. This notice operates under the existing SEBI framework for acquisition of shares through stock exchanges pursuant to tender offers under Takeover, Buyback, and Delisting regulations, as established by SEBI circular CIR/CFD/POLICYCELL/1/2015 (April 13, 2015) and CFD/DCR2/CIR/P/2016/131 (December 9, 2016), along with BSE’s revised guidelines.

Compliance Requirements

  • Trading Members and Custodians must note the buyback acquisition window dates and facilitate eligible shareholder participation
  • Participation is open to all eligible equity shareholders as on the record date (April 24, 2026) on a proportionate basis
  • Market participants must follow the Revised Guidelines per SEBI and BSE circulars cited above
  • Full details and the Letter of Offer are available on the BSE website (www.bseindia.com)

Important Dates

  • Record Date: Friday, April 24, 2026
  • Buyback Window Opens: Thursday, April 30, 2026
  • Buyback Window Closes: Thursday, May 7, 2026
  • SEBI Holiday (window closed): Friday, May 1, 2026
  • Notice Date: April 28, 2026

Impact Assessment

This buyback affects existing shareholders of Windlas Biotech Limited who are eligible as on the record date of April 24, 2026. The buyback represents 2.23% of total equity, at a premium price of INR 1,000 per share. Trading members and custodians must be prepared to process tender instructions during the April 30–May 7, 2026 window. The overall market impact is limited to Windlas Biotech’s shareholders and is operationally straightforward given the established BSE acquisition window mechanism.

Impact Justification

Directly affects shareholders and trading members of Windlas Biotech for a defined buyback window; limited to one company and a short offer period, hence medium ranking.